Human Collagen Elastin Composition for Soft Tissue Augmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current skin augmentation methods using synthetic and animal-derived materials face issues such as immune reactions, calcification, and viscosity problems, limiting their effectiveness and safety for human use.
Innovation Solution
Development of injectable compositions comprising isolated human collagen and elastin, both derived from engineered or native vascular tissues, with a molecular weight greater than 100 kDa, and a pharmaceutically acceptable carrier, which are insoluble in water to prevent calcification and immune responses, combined with glycosaminoglycans and active agents for enhanced tissue augmentation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If animal-derived collagen is used for skin augmentation, then tissue bulk and structural support are improved, but immune reactions and inflammation occur due to foreign antigens
Solution Approach 1:
The patent uses human collagen instead of animal collagen, creating a copy of the natural human extracellular matrix that avoids immune recognition. The human collagen is derived from engineered vascular tissue or micro-bead culture, providing identical molecular structure to host collagen, thereby eliminating antigenicity while maintaining tissue bulk and structural support functions.
Solution Approach 2:
The patent specifies precise molecular weight parameters for the collagen (100-500 kDa) and elastin (>100 kDa) to optimize their biocompatibility and functional properties. These parameter changes ensure the materials integrate properly with human tissue while maintaining the desired mechanical properties for skin augmentation.
2Strength
If elastin is used for skin augmentation, then elasticity and skin turgor are improved, but calcification occurs upon implantation
Solution Approach 1:
The patent uses human elastin derived from engineered vascular tissue or native vascular tissue, creating a biocompatible copy that matches human tissue composition. This eliminates the calcification problem associated with animal-derived elastin by ensuring molecular identity with host tissue, thereby maintaining elasticity without generating harmful calcification reactions.
Solution Approach 2:
The patent specifies that the elastin must have a molecular weight greater than 100 kDa and be substantially insoluble in water, which are critical parameter changes that prevent calcification while preserving elasticity. These parameter specifications ensure the elastin integrates safely into human tissue without triggering calcification pathways.
3Object-affected harmful factors
If synthetic materials like silicone and oils are used for tissue bulking, then non-immuneogenicity is achieved, but viscosity becomes very high and injection becomes difficult
Solution Approach 1:
The patent specifies precise concentration parameters for collagen (10-100 mg/ml, preferably 30 mg/ml) and elastin (2-60 mg/ml, preferably 3-30 mg/ml) to optimize the balance between biocompatibility and injectability. These parameter optimizations ensure the composition remains sufficiently viscous to maintain structural integrity while being injectable through standard medical equipment, resolving the contradiction between non-immuneogenicity and ease of injection.
4Object-generated harmful factors
If hyaluronic acid from rooster combs is used, then non-calcifying property is achieved, but viscosity is high and non-human origin causes immune concerns
Solution Approach 1:
The patent uses human collagen and elastin derived from engineered or native human vascular tissue, creating a complete copy of the human extracellular matrix system. This approach eliminates both the calcification issue (by using human rather than animal materials) and the immune reaction problem (by ensuring molecular identity with host tissue), providing a superior alternative to rooster comb hyaluronic acid.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides compositions comprising isolated human collagen, isolated human elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.